AMP-activated protein kinase as a therapeutic target for diabetes

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 2, 2007, Pages 123-127

  Leff, Todd ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; A 769662; ADENOSINE TRIPHOSPHATE; ADIPONECTIN; ANTIDIABETIC AGENT; GLUCOSE; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; THIENOPYRIDINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CALORIC INTAKE; DIABETES MELLITUS; DRUG POTENCY; DRUG STRUCTURE; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SINGLE DRUG DOSE;

EID: 41949086505     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.08.002     Document Type: Review

References (25)

1. Hardie D.G., et al. AMP-activated protein kinase - development of the energy sensor concept. J. Physiol. 574 Pt 1 (2006) 7-15
2. Kola B., et al. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 17 (2006) 205-215
3. Long Y.C., and Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 116 (2006) 1776-1783
4. Steinberg G.R., and Jorgensen S.B. The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev. Med. Chem. 7 (2007) 519-526
5. Holmes B.F., et al. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. 87 (1999) 1990-1995
6. Fryer L.G., et al. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. Biochem. J. 363 Pt 1 (2002) 167-174
7. Bergeron R., et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50 (2001) 1076-1082
8. Fiedler M., et al. 5-aminoimidazole-4-carboxy-amide-1-beta-D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice. Diabetologia 44 (2001) 2180-2186
9. Song X.M., et al. 5-aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 45 (2002) 56-65
10. Lochhead P.A., et al. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 (2000) 896-903
11. Andreelli F., et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147 (2006) 2432-2441
12. Foretz M., et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54 (2005) 1331-1339
13. Leclerc I., et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E1023-E1031
14. Richards S.K., et al. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J. Endocrinol. 187 (2005) 225-235
15. Arad M., et al. AMP-activated protein kinase in the heart: role during health and disease. Circ. Res. 100 (2007) 474-488
16. Corton J.M., et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 229 (1995) 558-565
17. Kirpichnikov D., et al. Metformin: an update. Ann. Intern Med. 137 (2002) 25-33
18. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest 108 (2001) 1167-1174
19. Hardie D.G. Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 131 (2006) 973 author reply 974-975
20. Brunmair B., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 (2004) 1052-1059
21. Saha A.K., et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys Res. Commun. 314 (2004) 580-585
22. Yamauchi T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13 (2007) 332-339
23. Zhao G., et al. Discovery and SAR development of thienopyridones: A class of small molecule AMPK activators. Bioorg. Med. Chem. Lett. 17 (2007) 3254-3257
24. Cool B., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3 (2006) 403-416
25. Hawley S.A., et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51 (2002) 2420-2425